Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up A total of 962 cases of CML on ...
Efficacy and safety of nilotinib 800 mg daily in early chronic phase Ph+ chronic myeloid leukemia: Results of a phase II trial at 2 years. Background: BCR-ABL transcript levels have been reported to ...
December 7, 2009 (New Orleans, Louisiana) — Tyrosine kinase inhibitors that target BCR-ABL mutations, such as imatinib (Gleevec), have become standard therapy in the treatment of chronic myeloid ...
NEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its new quantitative BCR-ABL 2.0 panel, with features ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results